An interventional study of Proximal phalangeal level and Volar to the MCP-joint in Trigger Finger, Trigger Thumb and Minimally Invasive Surgery, sponsored by Sahlgrenska University Hospital. Active, not recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Sahlgrenska University Hospital · Not applicable, Interventional, and Treatment
This is a prospective randomized multicenterstudy focusing on PROMs after primary corticoid injection for triggerfinger with a comparison of two different injection techniques.
This study aims to compare two different methods of corticosteroid injections in patients with triggerfinger, and to study the effects of these injections by day-to-day self-assessment by the included study persons for four weeks. The patient assess: 1. Pain 2. Motion and 3. Triggering by VAS scale every day for four weeks.
93 studies on the registry are indexed under Trigger Finger Disorder; 22 are open to participants now.
This study's planned enrollment of 100 is above the median of 66 across 75 interventional studies indexed under Trigger Finger Disorder.
Browse Trigger Finger Disorder studies →Sahlgrenska University Hospital is the lead sponsor of 263 studies on the registry; 68 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:•
Exclusion Criteria:
injection in the the tendon sheet over proximal phalanx of finger
Procedure: Proximal phalangeal level
injection above the A1 pulley volar to the MCP joint
Drug: Volar to the MCP-joint
Injection of methyl prednisone and lidocaine in the tendon sheet at the level of the proximal phalanx
Injection of methyl prednisone and lidocaine in the tendon sheet volar to the MCP-joint
Pain after injection
Visual analouge scale (VAS), range 0-10, where 0 indicates "no pain" and 10 "maximum pain"
Time frame: Four weeks
Impairment of finger motion
Visual analouge scale (VAS), range 0-10, where 0 indicates "no impairment" and 10 "maximum impairment"
Time frame: Four weeks
Triggering
Visual analouge scale (VAS), range 0-10, where 0 indicates "no trigger phenomenon" and 10 "Trigger phenomenon all the time/ locked finger"
Time frame: Four weeks
Quick-DASH
generic handquestionaire, 11 items, 0 means normal hand function, 100 most impaired function
Time frame: Four weeks
Started Oct 2020 (actual). Primary completion is estimated for Nov 2027, 85 months after the start.
Of 34 interventional studies with no phase under Trigger Finger Disorder, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 41. This study's planned 85 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sahlgrenska University Hospital →